...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advances in therapy. >Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products
【24h】

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

机译：他氟前列素和替莫洛尔的固定剂量联合用药治疗开角型青光眼和眼高压：与其他固定组合产品的比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F-2 alpha analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin-timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (> 13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav(A (R)) (Alcon, Fort Worth, USA) and Ganfort(A (R)) (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed.
机译：最近开发了一种新的无防腐剂的固定剂量组合，该组合包括0.0015％的塔氟前列素，前列腺素F-2α类似物和0.5％的噻吗洛尔（TAF / TIM; Santen Oy，坦佩雷，芬兰），一种β-肾上腺素能拮抗剂。在开角型青光眼和高眼压症中，TAF / TIM降低的眼内压（IOP）与其他前列腺素-噻吗洛尔固定组合产品相似。高眼压的患者对TAF / TIM的反应良好，减少幅度高达40％（> 13 mmHg），甚至更高。与先前使用DuoTrav（A）（美国爱尔康堡，Fort Worth）和Ganfort（A）（美国爱尔冈州艾尔根）进行的对照和双掩蔽临床试验相比，TAF / TIM引起的浅表眼侧减少效果和较少的结膜充血。讨论了固定组合产品之间副作用差异的合理解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号